Management of Acute Cardiogenic Shock at the New Brunswick Heart Centre

Overview

In Atlantic Canada, acute myocardial infarction occurs at a rate of 2.9 % of the population and is the most common cause of cardiogenic shock (CS). In many studies, acute myocardial infarction accounts for up to 80% of the patients with CS. While there are different methods of treating patients with CS, the rate of mortality has not significantly improved over the years and remains as high as 50%. Recent studies have shown that a multi-modal, team-based approach can help improve patient outcomes; however, such a standardized approach is yet to be implemented in the New Brunswick Heart Centre (NBHC). The study aims to understand the difference in outcomes between two groups of patients treated for CS: SHOCK TEAM versus non-SHOCK TEAM. This is a retrospective study of 168 patients using the data from NBHC registry and patient charts. The study duration is 1 year. The primary outcome is hospital survival. Secondary outcomes include time from diagnosis to invasive monitoring and intervention. All data will be analyzed statistically between the two groups. The end goal of the study is to establish standard guidelines to treat CS patients and improve patient survival.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 13, 2021

Interventions

  • Other: Standard care
    • No interventions were used, as this is an observational study.

Arms, Groups and Cohorts

  • At- risk group (SCAI stages A, B)
    • Patients who had a SCAI stage A or B at any point during their stay at the New Brunswick Heart Centre, Saint John Regional Hospital. This group was compared with the cardiogenic shock group only for preliminary analysis.
  • Cardiogenic shock group (SCAI stages C-E)
    • Patients who had a SCAI (Society for Cardiovascular Angiography and Interventions) stage C-E at any point during their stay at the New Brunswick Heart Centre, Saint John Regional Hospital. This group was used for all subsequent analyses.

Clinical Trial Outcome Measures

Primary Measures

  • Percentage mortality
    • Time Frame: From the date of hospital admission at Saint John Regional Hospital to the date of discharge, assessed upto 6 months
    • Any in-hospital mortality (within Saint John Regional Hospital, another hospital after transfer)
  • Length of stay (LOS))
    • Time Frame: From the date of hospital admission at Saint John Regional Hospital to the date of discharge, assessed upto 6 months
    • LOS was considered only for patients who were discharged directly home from Saint John Regional Hospital
  • Discharge disposition
    • Time Frame: From the date of hospital admission at Saint John Regional Hospital to the date of discharge, assessed upto 6 months
    • Discharge of patients home, transfer to another hospital or to another institution (special care home, extra-mural home)
  • Percentage of missed opportunities
    • Time Frame: From the date of hospital admission at Saint John Regional Hospital to the date of discharge, assessed upto 6 months
    • Missed opportunities was defined as patients who suffered significant delays or those who did not receive any intervention

Secondary Measures

  • Time from diagnosis of shock to in-hospital processes
    • Time Frame: From the date of hospital admission at Saint John Regional Hospital to the date of discharge, assessed upto 6 months
    • Time gaps between the first diagnosis of a cardiogenic shock to in-hospital processes like invasive monitoring, cardiac catheterization or interventions (surgery, PCI, TAVI, IABP or ECMO).

Participating in This Clinical Trial

Inclusion Criteria

1) Any patient admitted to the CCU with a diagnosis of CS (SCAI groups C, D or E) at any point during their CCU care. Exclusion Criteria:

1) CS patients having SCAI groups A, B (this group was used only for preliminary analysis, hence this is the exclusion criteria for all final analyses).

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • New Brunswick Heart Centre
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dr. Jean-François Légaré, Head of Cardiac Surgery – New Brunswick Heart Centre
  • Overall Official(s)
    • Jean-François Légaré, M.D., Ph.D., Principal Investigator, New Brunswick Heart Centre

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.